Related Experiment Videos
Ticlopidine-induced severe cholestatic hepatitis.
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|September 2, 2000
Summary
This case study highlights severe cholestatic hepatitis in an 86-year-old woman due to ticlopidine, a drug for coronary artery disease. Regular liver function monitoring is crucial for patients on ticlopidine therapy.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Ticlopidine is an antiplatelet medication commonly prescribed for coronary artery disease.
- Adverse drug reactions, including liver injury, necessitate careful patient monitoring.
- Cholestatic hepatitis is a liver condition characterized by impaired bile flow.
Observation:
- An 86-year-old female patient developed severe cholestatic hepatitis after 6 weeks of ticlopidine treatment.
- Symptoms included nausea, vomiting, and jaundice, with total bilirubin levels up to 43 mg/dl.
- Diagnostic evaluations, including liver biopsy, confirmed cholestatic hepatitis, ruling out biliary obstruction.
Findings:
- This case represents the first reported instance of severe ticlopidine-induced cholestatic hepatitis in Taiwan.
- Ticlopidine-induced liver injury, while documented internationally, presents a significant concern.
- Histopathological findings were consistent with drug-induced cholestatic liver injury.
Implications:
- This case underscores the importance of monitoring liver function in patients receiving ticlopidine.
- Healthcare providers should be vigilant for potential hepatotoxicity associated with ticlopidine.
- Early detection and intervention are critical for managing drug-induced liver injury.